Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy

 
• By Derrick Gingery
  
Eye
The advisory committee voted that efficacy outweighed netarsudil's safety issues.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers